| Literature DB >> 21143754 |
Päivi Piirilä1, Mia Laiho, Pirjo Mustonen, Marit Graner, Anneli Piilonen, Merja Raade, Seppo Sarna, Veli-Pekka Harjola, Anssi Sovijärvi.
Abstract
Acute pulmonary embolism (PE) often decreases pulmonary diffusing capacity for carbon monoxide (DL,CO), but data on the mechanisms involved are inconsistent. We wanted to investigate whether reduction in diffusing capacity of alveolo-capillary membrane (DM) and pulmonary capillary blood volume (Vc) is associated with the extent of PE or the presence and severity of right ventricular dysfunction (RVD) induced by PE and how the possible changes are corrected after 7-month follow-up. Forty-seven patients with acute non-massive PE in spiral computed tomography (CT) were included. The extent of PE was assessed by scoring mass of embolism. DL,CO, Vc, DM and alveolar volume (VA) were measured by using a single breath method with carbon monoxide and oxygen both at the acute phase and 7 months later. RVD was evaluated with transthoracic echocardiography and electrocardiogram. Fifteen healthy subjects were included as controls. DL,CO, DL, CO/VA, DM, vital capacity (VC) and VA were significantly lower in the patients with acute PE than in healthy controls (P < 0.001). DM/Vc relation was significantly lower in patients with RVD than in healthy controls (P = 0.004). DM correlated inversely with central mass of embolism (r = -0.312; P = 0.047) whereas Vc did not. DM, DL,CO, VC and VA improved significantly within 7 months. In all patients (P = 0.001, P = 0.001) and persistent RVD (P = 0.020, P = 0.012), DM and DL,CO remained significantly lower than in healthy controls in the follow-up. DM was inversely related to central mass of embolism. Reduction in DM mainly explains the sustained decrease in DL,CO in PE after 7 months despite modern treatment of PE.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21143754 PMCID: PMC3121963 DOI: 10.1111/j.1475-097X.2010.01000.x
Source DB: PubMed Journal: Clin Physiol Funct Imaging ISSN: 1475-0961 Impact factor: 2.273
The gender and anthropometric data of the patients with pulmonary embolism (PE) and the healthy control subjects
| Patients with PE | Healthy controls | Significance in | |
|---|---|---|---|
| Gender, male/female (number) | 23/24 | 6/9 | |
| Weight (kg) | 88·9 (18·1) | 73·0 (11·2) | 0·002 |
| Height (cm) | 172·0 (10·4) | 173·0 (11·1) | 0·730 |
| Age (year) | 56·1 (16·3) | 55·0 (16·5) | 0·881 |
| Smoking (pack-years) | 3·92 (7·6) | 2·67 (6·0) | 0·469 |
| Number (percent) of | |||
| non-smokers | 30 (63·8) | 11 (73·3) | 0·761 |
| smokers | 7 (14·9) | 2 (13·3) | |
| exsmokers | 10 (21·3) | 2 (13·3) | |
Chi-square test.
Spirometric data of patients and healthy controls. ANCOVA, used adjustment thoroughly in the methods chapter
| Patients ( | Controls ( | ||
|---|---|---|---|
| Variable | Mean (SD) | Mean (SD) | Significance of the difference |
| FVC (l) | 3·6 (1·2) | 4·1 (1·1) | 0·167 |
| FVC (%) | 88·3 (14·4) | 101·2 (17·1) | 0·039 |
| FEV1 (l) | 2·9 (0·93) | 3·4 (0·88) | 0·051 |
| FEV1 (%) | 88·0 (15·0) | 97·9 (28·3) | 0·098 |
| FEV1/FVC (%) | 80·8 (5·3) | 83·1 (6·3) | 0·180 |
| MEF 50 (l s−1) | 3·2 (1·4) | 4·2 (1·3) | 0·050 |
| MEF50 (%) | 74·8 (26·7) | 95·7 (27·9) | 0·014 |
FVC, forced vital capacity; VC, vital capacity.
Lung function data of patients and the healthy controls during the acute phase and at the recovery phase (7-month later). Mean and standard deviations are presented for all variables
| Variable | Patients, acute Phase | Controls, acute phase, | Statistical significance of comparison between patients and controls, acute phase ( | Patients, recovery phase | Statistical significance of comparison of patients between acute and recovery phases ( | Controls, recovery phase | Statistical significance of comparison between patients and controls, recovery phase ( |
|---|---|---|---|---|---|---|---|
| VC (l) | 3·5 (1·1) | 4·4 (1·1) | 0·022 | 3·80 (1·19) | <0·001 | 4·25 (1·17) | 0·514 |
| VC (%) | 83·3 (15·5) | 103·9 (14) | <0·001 | 90·3 (16·4) | <0·001 | 104·1 (15·2) | 0·478 |
| VA (l) | 4·3 (1·1) | 5·5 (1·3) | 0·002 | 4·7 (1·2) | <0·001 | 5·1 (1·15) | 0·432 |
| DL,CO (mmol min−1kPa−1) | 5·9 (1·8) | 8·3 (2·5) | <0·001 | 6·6 (2·1) | <0·001 | 8·2 (2·5) | 0·001 |
| DL,CO (%) | 73·7 (13·6) | 103·7 (15·2) | <0·001 | 81·3 (14·4) | <0·001 | 101·1 (15·59) | 0·003 |
| DL,CO/VA (mmol min−1kPa−1 l−1) | 1·39 (0·2) | 1·48 (0·2) | 0·008 | 1·30 (0·24) | 0·568 | 1·47 (0·27) | 0·012 |
| DL,CO/VA (%) | 94·6 (14·5) | 104·4 (13·7) | 0·032 | 96·3 (14·4) | 0·278 | 104·8 (17·2) | 0·025 |
| DM (mmol min−1 kPa−1) | 9·1 (3·0) | 13·9 (4·7) | <0·001 | 10·3 (3·8) | 0·001 | 13·6 (4·9) | 0·001 |
| DM (%) | 49·3 (15·6) | 72·3 (22·8) | <0·001 | 55·0 (19·3) | 0·003 | 71·7 (28·7) | 0·008 |
| Vc (ml) | 53·6 (16·1) | 63·9 (22·6) | 0·157 | 56·6 (16·5) | 0·159 | 69·3 (19·5) | 0·040 |
| Vc (%) | 68·7 (17·2) | 79·3 (19·4) | 0·062 | 72·0 (16·5) | 0·173 | 85·8 (18·1) | 0·049 |
| DM/Vc relation | 0·18 (0·09) | 0·22 (0·06) | 0·131 | 0·19 (0·09) | 0·770 | 0·21 (0·11) | 0·344 |
VA, alveolar volume; VC, vital capacity; DM, diffusing capacity of alveolo-capillary membrane; Vc, pulmonary capillary blood volume.
Level of significance according to Bonferroni correction is 0·004.
non-paired ANCOVA, adjustments are thoroughly given in the methods chapter.
paired t-test.
Figure 1Association of the diffusing capacity of the alveolo-capillary membrane with central embolism mass. The calculation was made with partial correlation with adjustment with age, smoking at pack years, height and weight.
The results of patients with and without right ventricular dysfunction (RVD) in echocardiography in the acute phase of pulmonary embolism. Also the comparisons of them with healthy controls are presented (non-paired ANCOVA)
| Variable | Patients without RVD ( | Patients with RVD ( | Healthy controls ( | Statistical significance of comparison between patients with and without RVD ( | Statistical significance of comparison between patients with RVD and controls ( | Statistical significance of comparison between patients without RVD and controls ( |
|---|---|---|---|---|---|---|
| VC (l) | 3·5 (1·2) | 3·4 (1·0) | 4·4 (1·1) | 0·618 | 0·013 | 0·064 |
| VC (%) | 83·3 (18·4) | 83·2 (13·5) | 103·9 (14) | 0·988 | <0·001 | 0·001 |
| VA (l) | 4·37(1·17) | 4·27 (0·98) | 5·5 (1·3) | 0·596 | 0·006 | 0·012 |
| DL,CO (mmol min−1 kPa−1) | 6·3 (1·9) | 5·67 (1·7) | 8·3 (2·5) | 0·218 | <0·001 | 0·002 |
| DL,CO (%) | 76·8 (14·2) | 71·0 (13·3) | 103·7 (15·2) | 0·139 | <0·001 | <0·001 |
| DL,CO/VA (mmol min−1kPa−1 l−1) | 1·46 (0·25) | 1·32 (0·23) | 1·48 (0·2) | 0·015 | 0·009 | 0·062 |
| DL,CO/VA (%) | 94·6 (14·5) | 104·4 (13·7) | 104·4 (13·7) | 0·025 | 0·007 | 0·293 |
| DM (mmol min−1 kPa−1) | 9·7 (3·0) | 8·5 (3·0) | 13·9 (4·7) | 0·185 | <0·001 | 0·001 |
| DM (%) | 51·7 (16·4) | 46·4 (14·5) | 72·3 (22·8) | 0·383 | <0·001 | 0·003 |
| Vc (ml) | 55·8 (17·6) | 51·4 (14·6) | 63·9 (22·6) | 0·446 | 0·333 | 0·211 |
| Vc (%) | 70·6 (18·9) | 66·0 (15·9) | 79·3 (19·4) | 0·441 | 0·043 | 0·195 |
| DM/Vc relation | 0·19 (0·12) | 0·17 (0·06) | 0·22 (0·06) | 0·484 | 0·004 | 0·674 |
VA, alveolar volume; VC, vital capacity; DM, diffusing capacity of alveolo-capillary membrane; Vc, pulmonary capillary blood volume.
Level of significance according to Bonferroni correction is 0·004.
non-paired ANCOVA, adjustments are thoroughly explained in the methods chapter.
Figure 2Diffusing capacity of membrane in the recovery phase. A suggestive difference existed between patients with and without right ventricular dysfunction (RVD), a significant difference between patients without RVD and healthy controls, as well as between patients with RVD and healthy controls (ANCOVA, adjustment according to age, height, weight and smoking). The level of significance after Bonferroni correction is 0·02.
Figure 3Diffusing capacity (DL,CO) in the recovery phase. A significant difference existed between patients without right ventricular dysfunction (RVD) and healthy controls and between patients with RVD and healthy controls (ANCOVA, adjustment according to smoking). The level of significance after Bonferroni correction is 0·02.